ProfileGDS5678 / 1450915_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 86% 85% 85% 85% 89% 88% 86% 87% 86% 88% 84% 87% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.6173187
GSM967853U87-EV human glioblastoma xenograft - Control 26.5951786
GSM967854U87-EV human glioblastoma xenograft - Control 36.3385385
GSM967855U87-EV human glioblastoma xenograft - Control 46.5025385
GSM967856U87-EV human glioblastoma xenograft - Control 56.3473585
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.7650989
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.669888
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.5275686
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.5907587
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.5916786
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.781988
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.3239584
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.6011487
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.5421786